Triple Negative Breast Cancer and Stunning Biological Drug, IMMU-132
FDA may approve new biological drug called IMMU-132 for treating patients with triple negative breast cancer On a personal note “My mother died of triple-negative
A combination with a new biological drug, Navicixizumab, Shows Benefit in Ovarian Cancer
New Trial – Ovarian Cancer Data from the phase Ib study were made available as part of the virtual platform for the SGO 2020 Annual Meeting
Corona Virus and Cancer
What is the link between the corona virus and cancer? The world is experiencing an outbreak of a new betacoronavirus known as Severe Acute Respiratory
FDA Grants Breakthrough Therapy Designation to JNJ-6372 in mNSCLC
Published on March 10, 2020 Background The FDA granted Breakthrough Therapy designation to JNJ-61186372 (JNJ-6372) for the treatment of patients with Metastatic Non-Small Cell Lung
Does genetic test extends the lives of Pancreatic Cancer patients?
Currently, it does not seem so and so one should think and think again about doing them especially for their high cost. Published on March
Proton or Photon Radiation?
Published on February 25, 2020 Background Many people with locally advanced cancers are treated with a combination of chemotherapy and either photon or proton radiation.
Metastatic Renal Cell Cancer, mRCC – Promising Treatment Option with Keytruda + Avastin
Published on February 25, 2020 Background This phase Ib/II study was designed to evaluate the safety and efficacy of a novel immunotherapy and VEGF-directed therapy
Breakthrough Data of DPX-Survivac immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
Published on February 26, 2020 Background In heavily pretreated patients, for whom there remains a tremendous unmet need with limited options beyond single-agent chemotherapy, which
CAR-T cell therapy brings new hope for Mesothelioma patients but is hard to get
Background While standard protocols such as chemotherapy are still widely used, clinical trials are supporting the discovery of new treatments and some have proven to
Kidney cancer – Novel drug shows promise in advanced disease
Published on February 15, 2020 Background Scientists report promising activity of the novel an oral first-in-class MK-6482 drug that targets a key driver of clear
A New Targeted Therapy Pill Extends Lives of Patients with Metastatic Renal Cell Carcinoma, RCC
Background In the phase III trial, more than 300 patients with metastatic RCC were randomly chosen to receive Fotivda (Tivozanib) or Nexavar (Sorafenib) for a
Gastric Cancer – 83.7% respond to Opdivo with Taxol plus Cyramza
The triplet of Opdivo, Cyramza and Paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.
